GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Gilead Sciences, Inc. (GILD) [hlAlert]

Rating:
Overweight
GILD
up 72.59 %

Gilead Sciences, Inc. (GILD) upgraded to Overweight by Atlantic Equities

Posted on: Friday,  Jul 26, 2013  8:25 AM ET by Atlantic Equities

Atlantic Equities rated Overweight Gilead Sciences, Inc. (NASDAQ: GILD) on 07/26/2013, when the stock price was $62.57. Since
then, Gilead Sciences, Inc. has gained 72.59% as of 10/28/2015's recent price of $107.99.
If you would have followed this Atlantic Equities's recommendation on GILD, you would have gained 72.59% of your investment in 824 days.

Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in areas of unmet medical need. The Company has United States and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Canada, France, Germany, Greece, Ireland, Italy, New Zealand, Portugal, Spain, Switzerland, Turkey, United Kingdom, and United States. Its commercial team promotes Truvada, Viread, Emtriva, Hepsera, AmBisome, Letairis, and Flolan through direct field contact with physicians, hospitals, clinics, and other healthcare providers. Gilead?s corporate partner, Astellas Pharma, Inc. (Astellas), promotes and sells AmBisome in the United States, Canada, Europe, Australia, and New Zealand. In May 2008, the Company acquired Navitas Assets, LLC?s. In April 2009, the Company announced the completion of its acquisition of CV Therapeutics, Inc.

Atlantic Equities
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/26/2013 8:25 AM Buy
None
62.57
as of 12/13/2013
1 Week down  -3.50 %
1 Month up  4.23 %
3 Months up  12.38 %
1 YTD up  14.11 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/5/2013 8:25 AM Hold
None
40.54

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy